Teva Pharmaceutical Industries Ltd. (TEVA) said it currently expects fiscal 2012 non-GAAP earnings per share between $5.30 and $5.40, whereas 28 analysts estimate earnings per share of $5.59 for the year.
For the full year 2012, the company sees total net sales of around $20 billion - $21 billion, consisting of total U.S. net sales of $10.5 billion, total European net sales of $5.8 billion, and total ROW net sales of $4.2 billion. Analysts project sales of $21.27 billion for 2012.
For comments and feedback: editorial@rttnews.com